New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 8, 2013
07:48 EDTLCILannett price target raised to $9 from $6 at Oppenheimer
Oppenheimer increased its price target on Lannett after the company reported higher than expected Q2 EPS. The firm notes that the company may be first-to-file for approval of thalidomide, now believed to represent a generic opportunity of 200M, and it maintains an Outperform rating on the shares.
News For LCI From The Last 14 Days
Check below for free stories on LCI the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 17, 2014
11:01 EDTLCIActavis drops after NY AG seeks to block Alzheimer drug switch
Subscribe for More Information
September 16, 2014
07:55 EDTLCILannett voluntarily conducts internal review in response to CT AG inquiry
Subscribe for More Information
September 10, 2014
13:36 EDTLCILannett receives FDA approval for oxycodone hydrochloride oral solution
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use